Analysts Set Amylin, Bankrate, Estee Lauder, Humana at Outperform Stock Rating

Humana Inc. (NYSE:HUM): After Humana reported higher than expected Q4 EPS, Oppenheimer believes that the company’s guidance was favorable while its growth outlook remains intact. The firm reiterates a $98 target and Outperform rating.

Amylin Pharmaceuticals, Inc.(NASDAQ:AMLN): After Amylin reported Q4 product sales that BMO Capital views as strong and the company announced the recent approval of weekly GLP-1 brand BYDUREON, the firm believes that Amylin’s base business has improved while BYDUREON is set for a strong launch. The firm maintains an Outperform rating.

Estee Lauder Companies Inc.(NYSE:EL): After Estee Lauder reported in-line Q2 EPS but mixed guidance, BMO Capital believes that the company’s strategy is effective. The firm continues to expect the company to generate mid-to high-teens EPS growth for the next several years, and it maintains an Outperform rating on the stock.

Bankrate Inc (NYSE:RATE): RBC Capital is somewhat concerned that Bankrate is generating lower quality revenue, but the firm recommends adding to positions in the stock if it drops to the low $20s. The firm raised its target on the shares to $26 from $24 while maintaining an Outperform rating. Limited(NASDAQ:CYOU): Brean Murray lowered its price target on following solid Q4 results but weak guidance. The firm expects margin contraction with the investment in a new game platform but believes the company is developing a solid pipeline and a diversification of its revenue source. Shares remain Buy rated.

Want news like this in real-time so you can get an edge? Click here for Wall St. Cheat Sheet Pro.

To contact the reporter on this story: Derek Hoffman at

To contact the editor responsible for this story: Damien Hoffman at